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Naveed Sattar* and Jason MR GillAbstract
Background: Although obesity and diabetes commonly co-exist, the evidence base to support obesity as the major
driver of type 2 diabetes mellitus (T2DM), and the mechanisms by which this occurs, are now better appreciated.
Discussion: This review briefly examines several sources of evidence – epidemiological, genetic, molecular, and
clinical trial – to support obesity being a causal risk factor for T2DM. It also summarises the ectopic fat hypothesis
for this condition, and lists several pieces of evidence to support this concept, extending from rare conditions and
drug effects to sex- and ethnicity-related differences in T2DM prevalence. Ectopic liver fat is the best-studied
example of ectopic fat, but more research on pancreatic fat as a potential cause of β-cell dysfunction seems
warranted. This ectopic fat concept, in turn, broadly fits with the observation that individuals of similar ages can
develop diabetes at markedly different body mass indexes (BMIs). Those with risk factors leading to more rapid
ectopic fat gain – for example, men (compared with women), certain ethnicities, and potentially those with a family
history of diabetes, as well as others with genes linked to a reduced subcutaneous adiposity – are more likely to
develop diabetes at a younger age and/or lower BMI than those without.
Summary: Obesity is the major risk factor for T2DM and appears to drive tissue insulin resistance in part via gain of
ectopic fat, with the best-studied organ being the liver. However, ectopic fat in the pancreas may contribute to
β-cell dysfunction. In line with this observation, rapid resolution of diabetes linked to a preferential and rapid reduction
in liver fat has been noted with significant caloric reduction. Whether these observations can help develop better
cost-effective and sustainable lifestyle /medical interventions in patients with T2DM requires further study.
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Although obesity and type 2 diabetes mellitus (T2DM)
commonly co-exist, the evidence to show that obesity is
a cause of T2DM, and the mechanism by which it does
so are only now beginning to be fully appreciated. Here,
we discuss the range of evidence to support this view.
We also describe the concept of ectopic fat as an im-
portant mechanistic link between obesity and T2DM in
many individuals.Discussion
Epidemiological associations
The strong epidemiological link between obesity and
T2DM in general is, of course, well described [1]. The
relative risks (RRs) for diabetes with rising obesity are in
fact among the highest for any risk factors for any* Correspondence: naveed.sattar@glasgow.ac.uk
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unless otherwise stated.disease, with around a 50- to 80-fold increase in T2DM
risk for a BMI of over 35 kg/m2 compared with a BMI
of less than 23 kg/m2 in populations of white European
descent (Figure 1) [2]. As a result, BMI can account for
a third to half of the weighting for T2DM risk scores.
Thus, the increasing level of obesity is a key driver for
the rising T2DM levels around the world, alongside im-
proved survival of patients with diabetes due to lower
death rates, and rising life expectancy in general. Unsur-
prisingly, therefore, any simple measure of adiposity
alone (for example BMI, waist circumference or waist/
hip ratios) can predict incident T2DM, with area under
the curve (AUC) for receiver operator characteristic
(ROC) ranging from 0.66 to 0.73 [3].Genes strengthen causal links between obesity and
diabetes
The most important gene for obesity so far discovered,
FTO (fat mass and obesity-associated protein), was first
reported to be linked to T2DM by Frayling et al. in 2007l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Relationship between body mass index (BMI) and risk for diabetes in US Health Professionals, derived from data extracted
from Chan et al. [2].
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for high-risk variants of the FTO gene, and this is associ-
ated with an average body weight 3 to 4 kg greater than
normal. However, the higher risk for T2DM in Europeans
is completely abolished after adjusting for BMI, suggesting
that the risk conferred by FTO is mediated via higher body
mass in this ethnic group, although other data suggest that
in other ethnicities, FTO may influence T2DM risk in part
independent of BMI [5]. Multiple other genes are linked
to T2DM risk, most being linked to β-cell dysfunction
rather than insulin resistance, as reviewed by Loos and
Bouchard [6]. In terms of T2DM risk assessment, how-
ever, there is no benefit in genotyping individuals for their
T2DM genes because such information does not improve
upon the risk prediction achievable by using a simpler
clinical phenotype and knowledge of family history of
T2DM [7]. Nevertheless, continued work on T2DM-
related genes should help strengthen causal inferences on
new risk pathways.
Evidence for the ectopic fat hypothesis in T2DM
Surprisingly, the pathophysiological basis for T2DM
continues to attract debate. What is clear, however, is
the emergence of one major hypothesis, namely that of
ectopic fat leading to organ-specific insulin resistance
via a process termed ‘lipotoxicity’ [8]. Many individuals
prone to T2DM appear to show a greater propensity to
accumulate visceral fat for a given weight; interestingly,
this characteristic may be a downstream consequence of
an ‘impaired’ subcutaneous fat storage capacity, the
mechanisms for which deserve greater attention. As ex-
treme example of this concept is lipodystropy; individ-
uals with this condition have an impaired ability to store
subcutaneous fat, and consequently with even modest
weight gain, they accumulate fat in visceral and ectopictissues (for example, the liver), leading in turn to marked
insulin resistance [9]. At the other extreme are many in-
dividuals, particularly women, who, despite attaining
very high BMIs (as high as 50 to 60 kg/m2), remain
insulin-sensitive, normoglycaemic and normolipaemic.
Imaging studies show these individuals to have low
levels of visceral and ectopic fat but a high subcutaneous
fat content [10]. A pharmacological example underlying
the importance of ectopic fat to dysglycaemia comes from
the observation that peroxisome proliferator-activated re-
ceptor (PPAR)-γ agonists (thiazolidenediones) lower glu-
cose levels despite increasing the patient’s weight. They
appear to do so by redistributing fat away from the liver
and towards an expanded subcutaneous pool [11,12]. Fi-
nally, transplantation of normal adipose tissue in the sub-
cutaneous region of lipoatrophic mice, which are normally
severely insulin-resistant, removes their excess hepatic fat
and normalises hepatic insulin sensitivity [13].
Ethnicity, sex, and the ectopic fat hypothesis
There are substantial ethnic differences in diabetes risk.
For example, South Asians develop T2DM at lower BMI
levels and around a decade earlier in life than white
Europeans [14]. Using UK Biobank data, we have re-
cently shown that South Asians with BMI of 22 kg/m2
have equivalent prevalence of T2DM to white Europeans
with BMI of 30 kg/m2. The corresponding BMIs for
Chinese men and women are 26 and 24 kg/m2, respect-
ively [15]. These remarkable findings help to explain
why T2DM rates are rapidly escalating as obesity levels
rise in countries such as India and China. A key reason
for the greater increase in diabetes risk per unit increase
in BMI in South Asians compared with Europeans may
be due to a reduced capacity in South Asians to store fat
in the primary superficial subcutaneous adipose tissue
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ary deep subcutaneous and visceral fat compartments,
and potentially the liver [16]. Indeed, there is some evi-
dence of differences in morphology of subcutaneous ab-
dominal adipose cells in South Asians compared with
Europeans, consistent with reduced capacity to store fat
in this depot [17-19], and other evidence suggests that
South Asians may have higher levels of liver fat than
Europeans [19,20]. Current evidence on ethnicity and
ectopic fat is limited by its cross-sectional nature, and
further research evaluating ethnic differences in the lon-
gitudinal changes in subcutaneous fat storage, adipocyte
morphology and function, and ectopic fat deposition
with increasing adiposity may yield important insights
into the mechanisms underpinning the substantial ethnic
differences in diabetes risk.
In terms of sex, we recently showed that men develop
diabetes at lower average BMIs compared with women
at most adult ages [21]. This finding is consistent with
the observation that adult men have greater levels of liver
fat and insulin resistance than women of comparable BMIFigure 2 Simple concept of ectopic fat and development of insulin re
development and location of ectopic fat in individuals once they have ‘ove
such as sex (females have greater storage capacity), genetics (with family h
ethnicity (for example, South Asians) and ageing appear to have relevance
such as smoking, may also be relevant but more data are needed to exam
closer to the time of development of T2DM whereas muscle insulin resista
to vascular dysfunction via a process of adverse vasocrine signalling, leadin
resistance. Finally, some recent evidence indicates that excess fat may also
thus development of T2DM. Such excess pancreatic fat appears reversible,
T2DM who are on insulin.[22]. In general, women carry or have a greater subcutane-
ous fat storage capacity and, linked to this, carry less vis-
ceral fat than do men. Therefore, the average woman has
to put on more weight than the average man to reach the
point at which she overwhelms her subcutaneous stores
and promotes sufficient ectopic fat deposition to develop
hyperglycaemia.
Collectively, the foregoing observations suggest that
the preferential location of fat storage (subcutaneous
versus visceral/ectopic) at any given BMI in individuals
may be crucial to their risk of a metabolic disorder, in-
clusive of diabetes. Figure 2 summarises the concept of
ectopic fat.
As an example showing that differential BMI thresh-
olds depend upon several genetic factors, a 50 year-old
South Asian man with a strong family history of T2DM
has a near-equivalent 10 year risk (~13% QDdiabetes
risk score [23]) of T2DM at a BMI of 22 kg/m2) as an
age-matched white female with no family history of
T2DM with a BMI of nearly 40 kg/m2. Thus, sex and
ethnicity combine to profoundly influence diabetes risk,sistance and frank diabetes. A simple conceptual illustration on the
rwhelmed’ their ability to store safe subcutaneous fat. Certain factors
istory of type 2 diabetes mellitus (T2DM) as a broad proxy measure),
to an individual’s ability to store fat subcutaneously. Other factors,
ine this. In temporal terms, it may be that liver fat accumulation occurs
nce is a more proximal development. Perivascular fat may contribute
g in turn to impaired nutrient blood flow; that is, vascular insulin
accumulate in the pancreas to contribute to β-cell dysfunction, and
and could contribute to diabetes resolution even in some patients with
Sattar and Gill BMC Medicine 2014, 12:123 Page 4 of 6
http://www.biomedcentral.com/1741-7015/12/123and this is likely to reflect, in part, differences in propen-
sity for ectopic fat storage, although of course, other fac-
tors also contribute.
The crucial role of ectopic liver fat and related molecular
explanations
In terms of chronology, gain of liver fat appears to precede
development of T2DM in most individuals, whereas
muscle insulin resistance appears to be a longer-standing
and earlier abnormality [24]. Considerable recent work
has focused on the role of the liver in the development of
diabetes, and linked to this, the condition of non-alcoholic
fatty liver disease (NAFLD) has been shown to be very
common (>50%) in patients with T2DM, and is linked to
hepatic insulin resistance [25].
Although the above evidence is now well accepted, the
exact molecular mechanisms leading to excess hepatic
fat accumulation remain elusive. Some authors suggest
that hyperinsulinaemia drives hepatic de novo lipogen-
esis whereas others suggest continued excess energy in-
take, particularly in form of carbohydrate, to be the
main factor responsible for hepatic de novo lipogenesis
and hepatic fat excess [26]. Regardless of the relative
contributions of these two alternatives, excess hepatic fat
appears to be causally linked to hepatic insulin resistance
via a number of potential cellular pathways, including
deleterious impaired inflammatory signalling, endoplasmic
reticulum stress, excess production of reactive oxygen spe-
cies, mitochondrial dysfunction, accumulation of triglycer-
ides and/or fatty acyl intermediates, and activation of
serine-threonine kinases, as recently reviewed [27]. Recent
research has focused in particular on hepatic diacylglyc-
erol (DAG) excess being the main culprit leading to
insulin resistance [28]. DAG activates protein kinase CϵFigure 3 Biochemical findings supporting excess liver fat. This simple
fat and the common biochemical findings of high glucose, altered liver en
aminotransferase (AST)) and hypertriglyceridaemia. When these three bioch
are not excessive alcohol drinkers, the likelihood of non-alcoholic fatty liver(PKCϵ), resulting in decreased insulin signalling [28]. Indi-
viduals with excess hepatic fat or NAFLD are therefore
unable to suppress hepatic gluconeogenesis normally in
response to insulin, and the continued excessive hepatic
glucose production contributes to hyperglycaemia and de-
velopment of diabetes. The same individuals also show el-
evated very low density lipoprotein synthesis and thus
elevated circulating triglyceride levels, another example of
‘ectopic’ fat appearing in the circulation. The commonest
signal for raised liver fat in such individuals is raised liver
enzymes, in particular alanine aminotransferase (much
greater than aspartate aminotransferase) and/or γ-glutamyl
transpeptidase levels, are recently reviewed [25]. These
concepts are demonstrated in Figure 3.
It is thought that in individual destined to develop dia-
betes, at a given level of peripheral or hepatic insulin re-
sistance, the ability of the pancreas to hypersecrete
insulin is overwhelmed, and so frank diabetes ensues.
Pancreatic failure is thought to be largely genetically
governed, and as discussed before, multiple genes gov-
erning insulin secretion have been identified. However,
the possibility that excess fat accumulating in pancreas
can impair β-cell function is now also emerging [29].
Is type 2 diabetes reversible via loss of fat or ectopic fat?
The simple answer to this is ‘yes’. If we accept that obes-
ity is causally linked to diabetes and that some individ-
uals can lose considerable weight by surgical or dietary
means, diabetes must be reversible. In a recent meta-
analysis, Buchwald et al. demonstrated that a mean
weight loss of around 38.5 kg from a mean pre-surgery
BMI of around 48 kg/m2 led to diabetes remission in
around 78% of patients [30]. Whether some types of bar-
iatric surgery lead to greater diabetes remission for afigure signals the link between excess calories, leading to excess liver
zymes (alanine aminotransferase (ALT) much greater than aspartate
emical features are present in overweight or obese individuals who
disease (NAFLD) is high.
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fice to say, the greater the weight loss in general, the
greater the chance of T2DM remission. In a more recent
meta-analysis [31], patients with a shorter duration of
T2DM and lower fasting plasma glucose had higher re-
mission rates, though further randomised studies would
be helpful to support and extend these findings; in par-
ticular, there was sparse data for ethnic groups outside
of white Europeans. Perhaps most impressively, many
patients previously on insulin also had T2DM remission
[30,31] suggesting that, at least in some patients, pancre-
atic function previously thought to be completely lost
may be recoverable with substantial weight loss.
In terms of diet, the most recent notable study was led
by the Newcastle group of Taylor et al. [29]. This group
demonstrated normalisation of blood glucose in 11
patients with diabetes after 1 week of commencing a
600 kcal/day diet. They also demonstrated improvement
in liver fat levels, which fell from around 10% to an aver-
age within the normal range at 2.9% by week 8, as well
as an improvement in β-cell response, the latter poten-
tially linked to the observed reduction in pancreatic fat
[29]. These very impressive findings suggest that a rapid
resolution of hyperglycaemia can be achieved by sub-
stantial caloric reduction. They also suggest the occur-
rence of rapid and preferential liver fat loss because
hepatic triglyceride content decreased by an average of
30% during week 1 of intervention (P < 0.001), whereas
total weight reduced by only around 4%. The liver re-
sponse to insulin also improved by the end of week 1 so
that insulin suppression of hepatic glucose output im-
proved from a mean of 43% to 74%, the latter being
similar to weight-matched controls without diabetes.
These findings all fit with the concept that excess liver
fat is intrinsically linked to hepatic insulin resistance and
consequently higher fasting glucose levels. Why fat re-
duction should lead to improved β-cell function is not
entirely clear, but is an area in need of greater research.Table 1 Evidence linking obesity to type 2 diabetes
Type of
evidence
Findings
Epidemiological BMI is the dominant risk factor for type 2 diabetes. Wherea
once BMI levels reach around 30–35 kg/m2, RRs for diabete
35 kg/m2 versus BMI of 21 kg/m2.
Genetic Genes linked to higher BMI, in particular the FTO gene, hav
Mechanistic Ectopic fat in key organs that are relevant to glucose meta
ectopic fat via metabolic intermediates interferes with insu
and hypertriglyceridaemia. Characteristics linked to earlier e
ethnic origins.
Clinical BMI or waist size make up around half of the weighting in
patients with diabetes are obese.
Reversibility Weight loss via dietary or surgical methods can reverse T2D
suggesting improvements in β-cell function. Rapid reductio
the short term whereas diabetes remission appears to relat
BMI, body mass index; CVD, cardiovascular disease; RR, relative risk; T2DM, type 2 dOf course, these impressive short-term results are
merely proof of concept. Cutting energy intake to 600 kcal
per day is achievable for most over a short term but, in
reality, not sustainable for long periods. The clinical impli-
cations of these findings therefore need to further tested
in longer-term clinical trials, some of which have now
begun. Nevertheless, these observations support the ec-
topic fat hypothesis for T2DM.
Summary
In summary, it is clear that obesity is a major risk factor
for T2DM, and appears to drive tissue insulin resistance
via gain of ectopic fat, with the best-studied organ being
the liver. Excess liver fat, and its related condition of
NAFLD, is now recognised as a key part of the T2DM
puzzle. However, ectopic fat in pancreas may also impair
β- cell function, which is an area deserving of more re-
search. It is also clear that different individuals will start
to expand their ectopic stores at different BMIs and
levels of total adiposity, dependent upon their unmodifi-
able characteristics (age, sex, ethnicity, family history) so
that some groups, such as South Asian men with a fam-
ily history of T2DM, have a very high diabetes risk even
at modest BMIs. Recent genetic data add support to the
concept of a diminished subcutaneous capacity in lower
BMI individuals being linked to greater metabolic risk
[32]. Finally, the definitive evidence of a causal link be-
tween obesity and T2DM comes from interventions that
can lower weight substantially, either by surgery or diet.
Where studied, these studies support a rapid resolution
in diabetes linked to a preferential and rapid reduction
in liver fat, further supporting the ectopic fat hypothesis
for diabetes. The preceding observations are summarised
in Table 1. The challenge now is to take advantage of
such observations and translate into clinical improve-
ments. Considerable ongoing work is needed to de-
velop such clinical translation, which is crucially
important given the rising levels of T2DM worldwide,s RRs for CVD with rising BMI tend to be around twofold to threefold
s are often around a log scale higher, approaching 50 to 80 times at BMI
e been clearly shown to predict T2DM.
bolism appears to be crucial for tissue insulin resistance. In the liver,
lin signalling and thereby contributes to higher fasting glucose levels
ctopic fat gain include male sex, family history of diabetes and certain
diabetes risk scores, regardless of ethnicity. Moreover, around half of all
M and even some patients previously on insulin can show remission,
ns in glucose levels appear to relate to changes in liver fat content in
e to the amount of fat loss in the longer term.
iabetes mellitus.
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